09
Mar
2010
Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Coagulation, X - Inflammation, XX - MA
Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!